Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation

Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)

(2013) M. Valgimigli et al.   EUROPEAN HEART JOURNAL

Medical Management After Coronary Stent Implantation

(2013) Emmanouil S. Brilakis et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Drug-Eluting Coronary-Artery Stents

(2013) Giulio G. Stefanini et al.   NEW ENGLAND JOURNAL OF MEDICINE

ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT)

(2012) Jung-Sun Kim et al.   AMERICAN HEART JOURNAL

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction

(2012) et al.   CIRCULATION

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials

(2012) Salvatore Cassese et al.   EUROPEAN HEART JOURNAL

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

(2012) et al.   EUROPEAN HEART JOURNAL

2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)

(2012) Hani Jneid et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry

(2012) Franz-Josef Neumann et al.   EuroIntervention

Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents

(2011) Hyeon-Cheol Gwon et al.   CIRCULATION

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

(2011) et al.   EUROPEAN HEART JOURNAL

Optical coherence tomographic comparison of neointimal coverage between sirolimus- and resolute zotarolimus-eluting stents at 9 months after stent implantation

(2011) Jung-Sun Kim et al.   INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING

Clinical Evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries

(2011) Alan C. Yeung et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

(2011) Glenn N. Levine et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial

(2011) Sigmund Silber et al.   LANCET

Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial

(2011) Giulio G Stefanini et al.   LANCET

Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions

(2010) Laura Mauri et al.   AMERICAN HEART JOURNAL

Increased Risk of Bleeding in Patients on Clopidogrel Therapy After Drug-Eluting Stents Implantation

(2010) Thomas T. Tsai et al.   Circulation-Cardiovascular Interventions

Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)

(2010) et al.   EUROPEAN HEART JOURNAL

Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial

(2010) Elvin Kedhi et al.   LANCET

Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents

(2010) Seung-Jung Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents

(2010) Patrick W. Serruys et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study

(2009) Robert A. Byrne et al.   AMERICAN HEART JOURNAL

Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents

(2009) Gregg W. Stone et al.   CIRCULATION

Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period

(2009) S. Schulz et al.   EUROPEAN HEART JOURNAL

Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial

(2009) R. A. Byrne et al.   EUROPEAN HEART JOURNAL

Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007

(2008) et al.   EUROPEAN HEART JOURNAL